Effect of intraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam

British Journal of Clinical Pharmacology

Volumn 58, Issue 5, 2004, Pages 476-481

  Osanai, T ^a   Ohkubo, T ^a   Yasui, N ^b   Kondo, T ^b   Kaneko, S ^b  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Brotizolam; CYP3A4; Drug interaction; Itraconazole; Pharmacokinetics

Indexed keywords

ANTIFUNGAL AGENT; BROTIZOLAM; HYPNOTIC AGENT; ITRACONAZOLE; PLACEBO; AZEPINE DERIVATIVE; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; HYPNOTIC SEDATIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE DRUG DOSE; SOMNOLENCE; VISUAL ANALOG SCALE; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ORAL DRUG ADMINISTRATION; PSYCHOMOTOR PERFORMANCE;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; AZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; HUMANS; HYPNOTICS AND SEDATIVES; ITRACONAZOLE; MALE; PSYCHOMOTOR PERFORMANCE;

EID: 9144228695     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02208.x     Document Type: Article

References (26)

1. Jochemsen R, Hermans J, Van Boxtel CJ, Breimer DD. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol 1983; 16: 285S-90S.
2. 14C]-brotizolam in humans. Arzneimittelforschung 1986; 36: 578-86.
3. Bechtel WD. Pharmacokinetics and metabolism of brotizolam in human. Br J Clin Pharmacol 1983; 16: 279S-83S.
4. Danneberg P, Böke-Kuhn K, Bechtel WD, Lehr E. Pharmacological action of some known and possible metabolites of brotizolam. Arzneimittelforschung 1986; 36: 587-91.
5. Senda C, Kishimoto W, Sakai K, Nagakura A, Igarashi T. Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam. Xenobiotica 1997; 27: 913-22.
6. Kronbach T, Mathys D, Umeno M, Gonzales FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P4503A4. Mol Pharmacol 1989; 36: 89-96.
7. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996; 59: 514-9.
8. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-84.
9. Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wraight CE, Shader RI. Triazolam biotransformation by human liver microzoms in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-9.
10. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24: 475-90.
11. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-5.
12. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-7.
13. Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatry 1997; 134: 559-62.
14. Lingjaerde O, Ahlfors UC, Bech P, Dencher SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 76 (Suppl, 334): 11-100.
15. Osanai T, Ohkubo T. Development of high-performance liquid Chromatographic method for determination of brotizolam on clinical pharmacokinetic study. Anal Lett 2003; 36: 3025-34.
16. Ohkubo T, Osanai T. Determination of itraconazole in human plasma by high-performance liquid chromatography with solid-phase extraction. Ann Clin Biochem 2004; in press.
17. Jalava K-M, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin Pharmacol 1996; 51: 331-4.
18. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996; 60: 326-31.
19. Wang J-S, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Midazolam α-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol 1999; 85: 157-61.
20. Jalava K-M, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19: 609-13.
21. Lilija JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 2003; 73: 192-8.
22. Miyama T, Takanaga H, Matsuo H, Yamano K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y, Sawada Y. P-Glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 1998; 42: 1738-44.
23. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-Glycoprotein in the blood-brain barrier of mice influence the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
24. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with p-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998; 358: 289-94.
25. Fleishaker JC, Phillips JP, Eller MC, Smith RB. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation. J Clin Pharmacol 1989; 29: 543-9.
26. Kroboth PD, Bertz RJ, Smith RB. Acute tolerance to triazolam during continuous and step infusions: Estimation of the effect offset rate constant. J Pharmacol Exp Ther 1993; 364: 1047-55.